Evaluating anti-platelet antibodies in diagnosing autoimmune thrombocytopenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the role of anti-platelet antibodies in diagnosing immune thrombocytopenia (ITP), an autoimmune condition characterized by low platelet counts. Using the monoclonal antibody immobilization of platelet antigens (MAIPA) assay, the research aims to determine the presence of these antibodies and their contribution to establishing the autoimmune nature of thrombocytopenia. The study focuses on patients over 18 years old with confirmed thrombocytopenia, ensuring that other causes have been ruled out. Blood samples will be collected to analyze the presence of these antibodies and their potential impact on the diagnosis and prognosis of ITP.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years old;
* Patients with thrombocytopenia \<100 G/L, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear;
* No treatment started;
* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);
* Person affiliated or benefiting from a social security scheme.

Exclusion Criteria:

* Secondary ITP;
* False thrombocytopenia;
* Patients who have been transfused with platelets for less than 7 days with efficacy;
* Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria);
* Patient with acute leukemia;
* Pregnant or breastfeeding woman;
* False thrombocytopenia;
* Patient under guardianship, curatorship or any other legal protection regime.

Where it's running

• CHU de Bordeaux - service de médecine interne
  Pessac, France Recruiting

Study contacts

• Principal investigator: Jean-François VIALLARD, Prof — University Hospital, Bordeaux
• Study coordinator: Jean-François VIALLARD, Prof
• Email: jean-françois.viallard@chu-bordeaux.fr
• Phone: 05.57.65.64.83

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Estimating Platelet Counts with ROTEM PLTEM in Laboring Women with Low Platelets or Heavy Bleeding

  This study tests whether the PLTEM value from ROTEM sigma testing can quickly estimate platelet count in pregnant women with low platelets or severe postpartum hemorrhage to help decisions about anesthesia and transfusions.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid · NCT07616349

• GL-2045 safety and blood-count help for adults with ITP

  GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.

  Recruiting Phase 1 Gliknik Inc. · Leeds · NCT07605845

• Eltrombopag use in adults with primary ITP: real-world patterns and outcomes

  This study looks at how eltrombopag is used in adult patients with primary ITP and what outcomes are seen in routine care.

  Recruiting Novartis · Basel · NCT07587723

• Etamsylate versus placebo to prevent bleeding after stem cell transplant

  This will test whether etamsylate can reduce bleeding in adults with very low platelets after hematopoietic stem cell transplantation.

  Recruiting Phase 3 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07442513

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.